CITY OF INDUSTRY, Calif.--(BUSINESS WIRE)--April 21, 2006--AXM Pharma, Inc. (AMEX: AXJ - News), a manufacturer of proprietary and generic pharmaceutical and nutraceutical products for the Chinese and other Asian markets, announced today that it has received a letter from the Staff of the American Stock Exchange ("Amex" or the "Exchange") stating that it intends to proceed with the filing of an application with the Securities and Exchange Commission ("SEC") pursuant to Section 1009 of the Amex Company Guide to delist the Company's common stock from the Exchange.
